182 results on '"Scher, Jose U."'
Search Results
2. New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine
3. Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation
4. Auto-deconvolution and molecular networking of gas chromatography-mass spectrometry data.
5. Responsiveness and Minimum Clinically Important Difference in Patient‐Reported Outcome Measures Among Patients With Psoriatic Arthritis: A Prospective Cohort Study
6. Interleukin‐17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin‐25–Driven Intestinal Inflammation
7. KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease
8. Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis Via COX-1
9. Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study
10. Inflammasome Signaling and Impaired Vascular Health in Psoriasis
11. Responsiveness and Minimum Clinically Important Difference in Patient‐ReportedOutcome Measures Among Patients With Psoriatic Arthritis: A Prospective Cohort Study
12. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial
13. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism
14. COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: A prospective cohort study
15. Role of Intestinal Dysbiosis and Nutrition in Rheumatoid Arthritis
16. Gut Microbiota Perturbations in Reactive Arthritis and Postinfectious Spondyloarthritis
17. Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry
18. A Randomized Open-Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation
19. Low incidence and transient elevation of autoantibodies post mRNA COVID-19 vaccination in inflammatory arthritis
20. Low incidence and transient elevation of autoantibodies post mRNA COVID-19 vaccination in inflammatory arthritis.
21. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS – CoV ‐2 Vaccination
22. Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures
23. Diet-Induced Arthritis in Pigs: Comment on the Article by Scher et al
24. Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis
25. Review: Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases
26. Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis
27. Gut–Brain Axis Dysfunction May Be Associated With Psoriatic Arthritis: Comment on the Article by Scher et al
28. Decreased Bacterial Diversity Characterizes the Altered Gut Microbiota in Patients With Psoriatic Arthritis, Resembling Dysbiosis in Inflammatory Bowel Disease
29. The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New‐Onset Rheumatoid Arthritis
30. Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination
31. A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health
32. Auto-deconvolution and molecular networking of gas chromatography–mass spectrometry data
33. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis
34. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS–CoV‐2 Vaccination.
35. Periodontal disease, Porphyromonas gingivalis, and rheumatoid arthritis: what triggers autoimmunity and clinical disease?
36. Distinct Polysaccharide Utilization Profiles of Human Intestinal Prevotella copri Isolates
37. A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health.
38. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
39. Microbiota‐Dependent Involvement of Th17 Cells in Murine Models of Inflammatory Arthritis
40. COVID‐19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease‐Modifying Antirheumatic Drugs on Clinical Outcomes.
41. Leveraging the United States Epicenter to Provide Insights on COVID‐19 in Patients With Systemic Lupus Erythematosus.
42. Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis
43. Alteration of the intestinal microbiome characterizes preclinical inflammatory arthritis in mice and its modulation attenuates established arthritis
44. Aberrant intestinal microbiota due to IL-1 receptor antagonist deficiency promotes IL-17- and TLR4-dependent arthritis
45. The lung microbiota in early rheumatoid arthritis and autoimmunity
46. Reply to the comments by Lu and Hi
47. Periodontal Disease and Subgingival Microbiota as Contributors for RA Pathogenesis: Modifiable Risk Factors?
48. Reply
49. The microbiome in celiac disease: Beyond diet-genetic interactions
50. Review: Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.